Desvenlafaxine Reduced HAM-D17 Scores in Major Depressive Disorder Review
TL;DR: A 2026 narrative review in Clinical Drug Investigation argued that desvenlafaxine, a serotonin-noradrenaline reuptake inhibitor (SNRI), may be a first-line major depressive disorder option for selected patients, especially when fatigue, cognitive compla…
Read article